Hematide

PALO ALTO, Calif., Nov 01, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that Robert B. Naso, Ph.D., the company's executive vice president of Research and Development, plans to retire at the end of the year. Dr. Naso will remain active in the strategic management of Affymax as a consultant to the company. "I am proud of t...

PALO ALTO, Calif., Oct 30, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY) today announced that several presentations featuring Hematide, the company's lead product candidate in development globally with Takeda Pharmaceutical Company Limited for the treatment of anemia, will be presented at the American Society of Nephrology Renal Week 2007 in...

PALO ALTO, Calif., Oct 29, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that Arlene Morris, the company's president and chief executive officer, will present at the following events on November 5 and 6 in New York City. Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference New York Palace Hotel November 5, 2...

PALO ALTO, Calif. and OSAKA, Japan, Oct 17, 2007 /PRNewswire via COMTEX News Network/ -- Affymax, Inc. (Nasdaq: AFFY) and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that they have been awarded the 2007 Deal of Distinction Award from the Licensing Executives Society of the U.S. and Canada (LES) for their innovative global agre...

PALO ALTO, Calif. & OSAKA, Japan, Oct 11, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Company Limited (TOKYO:4502) today announced that Affymax has dosed the first patient in the Phase 3 clinical program of its lead investigational therapy, Hematide(TM), for the treatment of anemia in chronic renal failure patients...

PALO ALTO, Calif., Oct 02, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that Paul Cleveland, the company's executive vice president and chief financial officer, will present at the Natexis Bleichroeder Hidden Gems Conference, Monday, October 8, 2007, at 3:45 p.m. Eastern Daylight Time in New York. A live webcast of the pr...

PALO ALTO, Calif., Sep 19, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY) today announced that Paul Cleveland, the company's executive vice president and chief financial officer, will present at the UBS Life Sciences Conference on Wednesday, September 26, at 10:30 a.m. Eastern Daylight Time in New York. A live webcast of the presentation ...

PALO ALTO, Calif., Aug 30, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that Paul Cleveland, the company's executive vice president and chief financial officer, will present at The Bear Stearns Healthcare Conference on Tuesday, September 11, at 4:30 p.m. Eastern Time in New York. A live webcast of the presentation will be...

PALO ALTO, Calif., Aug 27, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that Arlene M. Morris, the company's president and chief executive officer, will present at the Thomas Weisel Partners Healthcare Conference 2007 on Thursday, September 6, at 11:30 a.m. Eastern Time in Boston. A live webcast of the presentation will b...

PALO ALTO, Calif., Aug 21, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY) today announced the appointment of Steven Love as vice president, Finance. Mr. Love, who is a Certified Public Accountant and has 15 years of financial management experience, joins Affymax as a member of the senior management team. "Affymax is continuing to grow and...

PALO ALTO, Calif., Aug 14, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that Robert F. Venteicher, Ph.D. has joined the company as vice president, Technical Operations. Dr. Venteicher has nearly 30 years of experience in pharmaceutical and biotechnology drug development. In this position, Dr. Venteicher will oversee manufactu...

PALO ALTO, Calif., Aug 13, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the second quarter ended June 30, 2007. The net loss for the second quarter of 2007 was $9.2 million compared to a net loss of $27.8 million for the second quarter of 2006. The net loss for the first six months of 2007 was $16.4 milli...

PALO ALTO, Calif., Jul 31, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY) today announced the promotions of Anne-Marie Duliege, M.D., M.S., to chief medical officer and Christine Conroy, PharmD., to vice president, Regulatory Affairs and Good Clinical Practice Compliance. "The promotions of Anne-Marie and Christine are a reflection of the...

PALO ALTO, Calif., Jul 24, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY) today announced that Peter R. Young, Ph.D. has joined the company in the newly created position of vice president, Research. Dr. Young joins the company with over 20 years of experience in pharmaceutical and biotechnology drug research in oncology, cardiovascular, metab...

PALO ALTO, Calif., Jul 16, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that it plans to initiate Phase 3 clinical studies with Hematide(TM) in chronic renal failure patients following recent discussions with the United States Food and Drug Administration (FDA) on the design of the Phase 3 clinical trial program. Hematide is ...

PALO ALTO, Calif., Jul 13, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) will host a teleconference and webcast on Monday, July 16, 2007, at 10:00 a.m. Eastern time to review its Hematide(TM) clinical development program. Hematide is the company's lead drug in development for the treatment of anemia. Interested parties can listen to the l...

PALO ALTO, Calif., Jun 25, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that additional Phase 2 clinical trial results for Hematide(TM) were presented at the European Renal Association-EDTA Congress being held in Barcelona, Spain by Iain C. Macdougall, M.D., a Hematide investigator from Kings College, London. Dr. Macdougall's...

PALO ALTO, Calif., Jun 13, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that Elizabeth A. Czerepak, a managing partner of the venture capital firm Bear Stearns Health Innoventures, resigned from its board of directors. The company intends to seek a replacement on its board for Ms. Czerepak. "We have been fortunate for the...

PALO ALTO, Calif., May 16, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Affymax, Inc. (Nasdaq: AFFY) today announced that Arlene M. Morris, the company's president and chief executive officer, will present at the 2007 Citi Global Healthcare Conference on Wednesday, May 23, at 2:30 p.m. Eastern Time at The Hilton New York. A live webca...